You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
A 24-week study compared the effectiveness and safety of Galvus (vildagliptin), a DPP-4 inhibitor, with Avandia (rosiglitazone), a thiazolidinedione, in a double-blind, randomized, controlled, multi-center study. Both drugs had similar effects on A1c’s: Galvus reduced A1c by 1.1 %, and Avandia reduced A1c by 1. 3%. Most notably, patients did not gain weight with Galvus, but gained an average of 3.4 pounds with Avandia.
Galvus, made by Novartis, is in the same class as sitagliptin (Januvia), another DPP-4 inhibitor. Unlike Januvia, Galvus has not been approved by the FDA. FDA approval was expected by November 2006, but then the FDA asked for more data about studies linking Galvus to skin lesions in monkeys. In late February 2007, the FDA asked for a clinical study in patients with kidney impairment. It now looks as if Galvus will not be approved by the FDA for a year or more.
Sources: Diabetes Care
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.